The re-engineering of neurotrophins, such as EPO, NGF, or multiple other neuroprotective neurotrophins, as BBB penetrating IgG-neutrophin fusion proteins, could lead to new treatments to repair dystrophic neurites in AD. Here, EPO is linked to Alzheimer disease.